secwatch.observer — SEC 8-K summary
======================================

Issuer:     Incannex Healthcare Inc. (IXHL)
CIK:        0001873875
Form:       8-K
Filed at:   2026-04-22T23:59:59+00:00
Accession:  0001213900-26-046408
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Incannex Healthcare PSX-001 aligns with Trump Executive Order accelerating psychedelic mental health treatments
--------------------------------------------------------------------------------

- White House Executive Order (April 18, 2026) directs FDA to prioritize psychedelic compounds with Breakthrough Therapy designations and creates Right to Try pathways.
- PSX-001 Phase 2 for GAD: 12.8-point HAM-A reduction vs 3.6 placebo (p<0.0001), 44% response rate, 27% remission rate, no serious adverse events.
- Company has over $70M cash, no debt; active U.S. IND; views Executive Order as reducing regulatory and commercial risk for psilocybin class.
- PSX-001 targets GAD affecting ~6.8M in U.S. and 280M globally; Phase 2 had single discontinuation across 73 patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1873875/000121390026046408/0001213900-26-046408-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1873875/000121390026046408/ea0287297-8k_incannex.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-046408

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer